Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,424,604 shares of the biopharmaceutical company's stock after selling 310,855 shares during the period. Principal Financial Group Inc. owned 0.12% of Bristol-Myers Squibb worth $124,406,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Addison Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 6.6% in the 3rd quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company's stock valued at $181,000 after acquiring an additional 192 shares during the last quarter. Symphony Financial Ltd. Co. increased its holdings in Bristol-Myers Squibb by 4.1% during the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company's stock valued at $288,000 after buying an additional 194 shares during the period. Blue Bell Private Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 200 shares in the last quarter. AMG National Trust Bank boosted its stake in Bristol-Myers Squibb by 1.0% in the third quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company's stock valued at $1,143,000 after acquiring an additional 201 shares in the last quarter. Finally, Westside Investment Management Inc. boosted its stake in Bristol-Myers Squibb by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company's stock valued at $367,000 after acquiring an additional 204 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

NYSE BMY traded up $0.12 on Monday, reaching $45.06. The company's stock had a trading volume of 11,809,862 shares, compared to its average volume of 15,568,044. The firm's 50 day moving average is $49.72 and its two-hundred day moving average is $50.23. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock has a market cap of $91.34 billion, a PE ratio of -14.52, a PEG ratio of 15.19 and a beta of 0.45. Bristol-Myers Squibb has a twelve month low of $43.33 and a twelve month high of $68.46.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts' consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm's revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.05 earnings per share. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.33%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio is -77.42%.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 18th. StockNews.com cut shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. Redburn Atlantic cut shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, Barclays dropped their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating for the company in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and an average target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.